SB216763

Catalog No.S1075

For research use only.

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.

SB216763 Chemical Structure

CAS No. 280744-09-4

Selleck's SB216763 has been cited by 77 publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Other GSK-3 Products

Biological Activity

Description SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.
Targets
GSK-3α [1]
(Cell-free assay)
GSK-3β [1]
(Cell-free assay)
34.3 nM ~34.3 nM
In vitro

SB 216763 displays similar potency for GSK-3β with 96% inhibition at 10 μM while exhibiting minimal activity against 24 other protein kinases including PKBα and PDK1 with IC50 of >10 μM. SB 216763 stimulates glycogen synthesis in human liver cells with EC50 of 3.6 μM, and induces dose-dependent transcription of a β-catenin-LEF/TCF regulated reporter gene in HEK293 cells with a maximum 2.5-fold induction at 5 μM. [1] SB 216763 protects the cerebellar granule neurones from apoptotic cell death induced by LY-294002 or potassium-deprivation in a concentration-dependent manner, with a maximal neuroprotection at 3 μM in contrast with the effect of lithium chloride at which 10 mM is required. SB 216763 at 3 μM also completely prevents death of chicken dorsal root ganglion sensory neurones induced by LY-294002 regardless of NGF. SB 216763 treatment at 5 μM markedly inhibits the GSK-3-dependent phosphorylation of neuronal-specific microtubule-associated protein tau in cerebellar granule neurones or recombinant tau in HEK293 cells, and induces increased levels of cytoplasmic β-catenin in both cells mimicking the effect of Wnt-mediated inhibition of GSK-3. [2] In pancreatic cancer cell lines including BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC, SB 216763 treatment at 25-50 μM reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis by 50% at 72 hours due to the specific down regulation of GSK-3β, while has no effect in HMEC or WI38 cell lines. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NHj1cXdHfW6ldHnvckBie3OjeR?= NYPiSVZkT2y7Y3;n[Y4he3mwdHjhd4Uh[WO2aY\peJkhd2ZiSFXLNlk{KGOnbHzzMEBqdmirYnn0bY9vKG:oIFfTT|Mu[mW2YTygSWM2OD1yLkNOwG0> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjl2MUOzNUc,OTJ7NEGzN|E9N2F-
HEK293 MV3GeY5kfGmxbjDhd5NigQ>? M3OwS2Vn\mWldHn2[UBkd26lZX70doF1cW:wIH;mJINwdXCxdX7kJIFo[Wmwc4Sg[4x6[2:pZX6gd5lvfGijc3Wgb4lv[XOnLUOgbY4hUEWNMkmzJINmdGy|LDDFR|UxRTBwMt88US=> NInZWHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG0PVY5PCd-MUWxOFk3QDR:L3G+
MIAPaCa2 NHzjbIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DBOFczKGi{cx?= NFW4TW9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOUUGSYVPhNkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTJ3zszN M{XldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{O4N|U2Lz5zOUOzPFM2PTxxYU6=
ST14A MUTGeY5kfGmxbjDhd5NigQ>? NFPhSpA3KGi{cx?= MlPJTY5pcWKrdHnvckBw\iCJU1utN{1j\XSjLX3l[IlifGWmIGfueEB{cWewYXzpcochcW5iaIXtZY4hW1RzNFGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[WOldX31cIF1cW:wIH;mJIJmfGFvY3Hz[YlvKGG{b4Xu[EBvfWOuZYXzJIFnfGW{IE[gbJJ{KGK7IH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz NGHp[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEewPFk{Pyd-MkC3NFg6Ozd:L3G+
neural precursor cells NYHa[ZVPTnWwY4Tpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKG6ndYLvd5Bp\XKnIIDyc4xq\mW{YYTpc44hd2ZibX;1d4UhdmW3cnHsJJBz\WO3coPvdkBk\WyuczDifUBOXFRiYYPzZZk> M3LtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO|Y{OTxxYU6=
ReNcell VM M3\re2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2XRZ|MhfU1? NIDtc|g4OiCqcoO= M{\RfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUnXOZ4VtdCCYTTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEOgeW0h[W[2ZYKgO|IhcHK| NYTnOoVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3NFg6OzdpPkKwO|A5QTN5PD;hQi=>
HepG2 MWrGeY5kfGmxbjDhd5NigQ>? MmXyN|QhfU1? NU\OcW1rOTJiaILz Mn6xTY5kemWjc3WgbY4h\2y3Y3;z[UBqdmOxcoDvdoF1cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDN2IIXNJIFnfGW{IEGyJIhzeyCkeTDncJVkd3OnIHHzd4F6 M2DrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[3NVUxLz5{NUS2O|E2ODxxYU6=
3T3L1 NX:2eY8xTnWwY4Tpc44h[XO|YYm= MUmzOEB2VQ>? NY\WWWhqOTJiaILz MoflTY5kemWjc3WgbY4h\2y3Y3;z[UBqdmOxcoDvdoF1cW:wIHnuJI1wfXOnIEPUN2wyKGOnbHzzJIF1KDN2IIXNJIFnfGW{IEGyJIhzeyCkeTDncJVkd3OnIHHzd4F6 Mo\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkexOVAoRjJ3NE[3NVUxRC:jPh?=
HepG2 M3X1S2Z2dmO2aX;uJIF{e2G7 NYq4V3ltOzRidV2= M2WzNlEzKGi{cx?= MmLxTY5pcWKrdHnvckBw\iCJU1uzZoV1[SCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC{YYTpc{Bw\iCyaH;zdIhwenmuYYTl[EBIWy:JUzDheEA{PCC3TTDh[pRmeiBzMjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4N{G1NEc,OjV2NkexOVA9N2F-
Sf9 NW\uTnVDTnWwY4Tpc44h[XO|YYm= MYqzNEBucW5? MWTJcohq[mm2aX;uJI9nKEeVS{Pi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCJU{GgZZMhe3Wkc4TyZZRmKGGwZDDb[4FudWF|Mm3BWHAh[W[2ZYKgN|AhdWmwIHL5JJNkcW6rdHzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yM{O4PO69VQ>? NX7RN3pnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human HDLM-2 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\i[3U{UW6qaXLpeIlwdiCxZjDoeY1idiCKRFzNMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyOUi0JO69VQ>? Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H1770 cell M3HQO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoP1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS5iSVO1NF0xNjJ7M{myJO69VQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human HOP-62 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Moe3TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg2OjV4IN88US=> NUjZPYVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human JAR cell M4DrVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnlUHpKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlExPDRizszN NH\SOno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human K5 cell MlLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\hUJpKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJktKEmFNUC9NU42OzZ7ODFOwG0> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human MV-4-11 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHwTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk43QTZ6NTFOwG0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human BT-549 cell MmHwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmP3TY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6Ozd4IN88US=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human LB2241-RCC cell NUnJO4NWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmCxTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi52Mki3OEDPxE1? NYjPZVhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human GAMG cell M{O5Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETue3lKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PDB7IN88US=> MlTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human HMV-II cell NV74ZoQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3sTnJKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPjd4MEeg{txO NIT5U3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human RS4-11 cell M{nxd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnaTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI1OTRzIN88US=> NXPRdJJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NCI-H1993 cell M2XjVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1X3bWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixPVk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC5|NkWzOEDPxE1? NYK5bm9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human IST-SL1 cell NIDGVllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M17CS2lvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLWPMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvODJyNDFOwG0> MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SK-OV-3 cell NYDXWIJ4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVH6[IM3UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS5zMECyJO69VQ>? NFT6SmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human ESS-1 cell MoLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUTCXFlwUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPTl6N{Kg{txO M3PVZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human G-361 cell MmnOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nWS2lvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4yPzl6IN88US=> MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human ALL-PO cell NV;TO5JtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlM1PzdizszN MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NB5 cell M4jobGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXz0PZpzUW6qaXLpeIlwdiCxZjDoeY1idiCQQkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4zOTV5IN88US=> NHjTflU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human DU-145 cell NUexbYdXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlY2OzVizszN NXPV[VI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NMC-G1 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJG5OSy2JMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlczPjRizszN M3PFUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human RPMI-7951 cell NHPUbVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1O2XWlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST23PVUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:OTFwN{i2OEDPxE1? NIHmU3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NCI-H2009 cell NEnvVnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDkTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOy5{NEK3JO69VQ>? NVvLXW1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human LoVo cell NIf4T5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6zO|cyKM7:TR?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human A2058 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XaRmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{41PjlizszN M4nkN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human D-566MG cell NX3jdHNRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYTGNG94UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTNwOUS4NUDPxE1? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human QIMR-WIL cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHZTY5pcWKrdHnvckBw\iCqdX3hckBSUU2ULWfJUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjZ|OUSg{txO M{jDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human S-117 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3LKNWlvcGmkaYTpc44hd2ZiaIXtZY4hWy1zMUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk41ODJ{IN88US=> M2npXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human YH-13 cell NEDyfmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEL6UWFKdmirYnn0bY9vKG:oIHj1cYFvKFmKLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPjh4NTFOwG0> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human IGROV-1 cell NHq4blhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\YTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVcvOjByMTFOwG0> NVnyUHFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BHT-101 cell MmSyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVK3WmZ4UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTdwNkC5PUDPxE1? NF[4W5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human MKN45 cell MnXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmD4TY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG4MlQyOjhizszN NHLIb|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human A498 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFH1fHZKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU41PTR7IN88US=> NI\ZToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human U-266 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLpT5pKdmirYnn0bY9vKG:oIHj1cYFvKFVvMk[2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvQDd7NzFOwG0> M{nHWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human BFTC-905 cell NV\F[ZhzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWjJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOTh5OTFOwG0> M3X5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human BxPC-3 cell M1XT[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3jmcWlvcGmkaYTpc44hd2ZiaIXtZY4hSniSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOzV3NDFOwG0> Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-SNU-1 cell MoHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LFRmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwNUW1PEDPxE1? NYrFRXd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SF539 cell MlvFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIPCNG5KdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlIvODF7ODFOwG0> NXT3XJlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human VA-ES-BJ cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zTfGlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOi53N{[zJO69VQ>? M1\hfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human HuO-3N1 cell Mlu1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrL[3BHUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:tN24yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjJwNkG1NUDPxE1? NVLhVGd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human EM-2 cell NIK0bm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DLRWlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKyMlY3QDlizszN M2Tz[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human T98G cell MlLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Mz6zNFA6KM7:TR?= NWPEeYZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW1783 cell MkLrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKzMlUzPDNizszN NYrFW|BxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NKM-1 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17ETmlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yN{45PTF{IN88US=> Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human KOSC-2 cell MonVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1O5XGlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvOTJ7MjFOwG0> Mn\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SW48 cell M4DndGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{ND62NFY4KM7:TR?= M4jTSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NCI-H28 cell M3HENmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\qT2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI2NjJzMESg{txO MnO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human 5637 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33kPWlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK1MlgyOTFizszN M{TCTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NB69 cell M2TCRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PjeWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK2MlE4PjRizszN MnfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human HT-29 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuNVc2OiEQvF2= NHPw[|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human PFSK-1 cell NFW4cYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYTJc|hKUW6qaXLpeIlwdiCxZjDoeY1idiCSRmPLMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy53OUOg{txO NEPkdYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human UACC-257 cell M2HpZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnNTY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI4Njd2MzFOwG0> NXnYc5JnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human D-423MG cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3r4[WlvcGmkaYTpc44hd2ZiaIXtZY4hTC12MkPNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI4NjlzME[g{txO M{L4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NH-12 cell M{HWOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVnJSVI4UW6qaXLpeIlwdiCxZjDoeY1idiCQSD2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjRyNUmg{txO NVmwO4xqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human DEL cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHuTY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT6wOFc1KM7:TR?= Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human LS-513 cell MmTUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnwdpFKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjF|M{Sg{txO M1q5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human NBsusSR cell M3;4VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3SxeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkK|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjV4N{ig{txO MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human BV-173 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTxOVlKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjd4NEmg{txO NVTVXGJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A101D cell M1j1WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3mdpJKdmirYnn0bY9vKG:oIHj1cYFvKEFzMEHEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|AvQTd6NDFOwG0> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human LU-134-A cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHFb5dKdmirYnn0bY9vKG:oIHj1cYFvKEyXLUGzOE1CKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzFwMEKzPEDPxE1? NXjVdJJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human ES3 cell M{Dhemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3vvNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|M4PiEQvF2= NHXwcI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NY cell MoHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYT2fI1zUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOyMlI6PjVizszN NHn2UGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NCI-H1975 cell NEXIO2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXi3VYhMUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE6PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mj6zOVgzKM7:TR?= M4LhUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human A704 cell M2OxW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND6yNFU6KM7:TR?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human SK-MEL-24 cell MkXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HtVWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwMkWyN{DPxE1? NFvvTXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human SW1088 cell NHTQeotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HuemlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvOzR3MjFOwG0> M2G4d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human SK-MEL-1 cell NYL6V2MyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XqPWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTygTWM2OD1|ND63NVQh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human MOLT-4 cell NFLzcFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIXQNZRKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM3NjF2Nkeg{txO MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human T47D cell MnHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1HZeGlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlE3PDdizszN MofoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SW1710 cell M1PHd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlM3ODhizszN MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human MKN7 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGrwNmJKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4xQTB7IN88US=> M3rhTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human CAL-72 cell M2fm[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO4MlEyPzhizszN NIPETpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human AGS cell NWPiTGh3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnHfI1KdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO4MlIxOzlizszN NYfEVmdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BE-13 cell NW\wUZFPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnITY5wUW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM5Njd5OEOg{txO MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human Calu-6 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NULJb|lkUW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{QS54OU[0JO69VQ>? NFG0PXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human CAL-27 cell M4LiNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLLTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OE4xODV2IN88US=> NV\B[5l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BB49-HNC cell NVPUbW9ST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MofjTY5pcWKrdHnvckBw\iCqdX3hckBDSjR7LVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ1NjB{N{ig{txO M17hdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
Assay
Methods Test Index PMID
Western blot c-Myb ; pGSK-3β / GSK-3β / E2F1 / β-catenin 21795403 28042322
Growth inhibition assay Cell viability 24779365
In vivo Administration of SB 216763 at 20 mg/kg significantly prevents lung inflammation and the subsequent fibrosis in bleomycin (BLM)-induced pulmonary inflammation and fibrosis model in mice by significantly blocking the production of inflammatory cytokines MCP-1 and TNF-α by macrophages, and significantly improves the survival of BLM-treated mice. SB 216763 treatment causes a significant reduction in BLM-induced alveolitis by inhibiting alveolar epithelial cell damage. [4]

Protocol (from reference)

Kinase Assay:[1]
  • GSK-3 activity assay:

    GSK-3 kinase activity is measured, in the presence of various concentrations of SB 216763, in a reaction mixture containing final concentrations of 1 nM human GSK-3α, 50 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM Mg-acetate, 7.5 mM β-mercaptoethanol, 5% (w/v) glycerol, 0.01% (w/v) Tween-20, 10% (v/v) DMSO, and 28 μM GS-2 peptide substrate. The GS-2 peptide sequence corresponds to a region of glycogen synthase that is phosphorylated by GSK-3. The assay is initiated by the addition of 0.34 μCi [33P]γ-ATP. The total ATP concentration is 10 μM. Following 30 minutes incubation at room temperature the assay is stopped by the addition of one third assay volume of 2.5% (v/v) H3PO4 containing 21 mM ATP. Samples are spotted onto P30 phosphocellulose mats and washed six times in 0.5% (v/v) H3PO4. The filter mats are sealed into sample bags containing Wallac betaplate scintillation fluid. 33P incorporation into the substrate peptide is determined by counting the mats in a Wallac microbeta scintillation counter.

Cell Research:[3]
  • Cell lines: BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of SB 216763 for 24, 48 and 72 hours. Relative cell viability is measured using the MTS assay. Apoptotic cells are determined by staining with Hoechst.
Animal Research:[4]
  • Animal Models: C57BL/6N mice with lung inflammation and fibrosis induced by bleomycin (BLM)
  • Dosages: 20 mg/kg
  • Administration: Intravenously

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.

4mg/mL

Chemical Information

Molecular Weight 371.22
Formula

C19H12N2O2Cl2

CAS No. 280744-09-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy SB216763 | SB216763 supplier | purchase SB216763 | SB216763 cost | SB216763 manufacturer | order SB216763 | SB216763 distributor